Document is current
Any future updates will be listed below
-
Authors
González, Alba Cervantes
Goossens, Julie
Campuzano, Elena Vera
Sala, Isabel
Sánchez-Saudinós, M. Belén
Rodríguez-Baz, Íñigo
Lidón, Laia
Perlaza, Danna
Bejanin, Alexandre
Haapasalo, Annakaisa
Fortea, Juan
Alcolea, Daniel
Lleó, Alberto
Vanmechelen, Eugeen
Belbin, Olivia
-
Funding
Funding for this research was provided by:
EU Joint Programme– Neurodegenerative Disease Research (AC21_2/00017)
EU Joint Programme– Neurodegenerative Disease Research (AC21_2/00017)
Instituto de Salud Carlos III (PI22/00611)
Instituto de Salud Carlos III (PI21/00327)
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (Program 1, Alzheimer disease)
Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR 2019 PROD 00088)
- License Information
-
More Information
Article History
Received: 19 November 2024
Accepted: 26 January 2025
First Online: 24 February 2025
Declarations
:
: This study was reviewed and approved by the IRB (Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau– IIB Sant Pau) and was conducted in accordance with the Declarations of Helsinki. All participants gave their written informed consent to participate in the study.
: Not applicable.
: E.V. is co-founder of ADx NeuroSciences NV, Zwijnaarde (Ghent), Belgium, J. G. is employee at ADx NeuroSciences NV. J.F. has served as a consultant for Novartis and Lundbeck, has received honoraria for lectures from Roche, NovoNordisk, Esteve and Biogen and served at advisory boards for AC Immune, Zambon and Lundbeck. D.A. participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U., Lilly and Esteve Pharmaceuticals. A.L. participated in advisory boards from Biogen, Eisai, Fujirebio-Europe, Novartis, NovoNordisk, Nutricia, Otsuka Pharmaceutical, and Zambón, and received speaker honoraria from Lilly, Biogen, KRKA and Zambon. D.A, J.F., A.L. and O.B. declare a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease) related to biomarkers included in this manuscript.
